Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

In this small study, huCART19-IL18 had a safety profile consistent with other CAR T-cell treatments and showed promising efficacy at low cell doses in patients with lymphoma after the failure of ...

Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part ...

A next-generation "armored" CAR T cell ... their lymphoma," said Jakub Svoboda, MD, an associate professor of Hematology-Oncology, who led the clinical trial at Penn Medicine's Abramson Cancer ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients ... ability to attack the cancer cells." ...

Anthony Cannella had twice faced down a rare and aggressive cancer only to see it come ... director of CAR T cell therapy and lymphoma at Hollings. Those patients typically had a "very, very ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...

A study shows that women with BRCA1 or BRCA2 mutations who have textured breast implants are at a 16-fold higher risk of ...